Inspirna, Inc.
3 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer (NCT05983367) | Inspirna, Inc. | 2023-10-10 |
| A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer (NCT03597581) | Inspirna, Inc. | 2018-06-05 |
Track Inspirna, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.